Pensionfund PDN purchased a new position in shares of Sabra Healthcare REIT, Inc. (NASDAQ:SBRA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 97,730 shares of the real estate investment trust's stock, valued at approximately $1,851,000. Sabra Healthcare REIT comprises about 1.2% of Pensionfund PDN's holdings, making the stock its 24th biggest holding.
Other institutional investors and hedge funds have also bought and sold shares of the company. Focus Partners Wealth increased its stake in shares of Sabra Healthcare REIT by 11.4% in the first quarter. Focus Partners Wealth now owns 23,146 shares of the real estate investment trust's stock worth $404,000 after acquiring an additional 2,375 shares during the period. Creative Planning lifted its position in Sabra Healthcare REIT by 17.2% during the second quarter. Creative Planning now owns 35,175 shares of the real estate investment trust's stock valued at $649,000 after purchasing an additional 5,168 shares during the period. Cetera Investment Advisers boosted its holdings in Sabra Healthcare REIT by 2.1% in the second quarter. Cetera Investment Advisers now owns 107,152 shares of the real estate investment trust's stock valued at $1,976,000 after purchasing an additional 2,203 shares during the last quarter. Franklin Resources Inc. grew its position in Sabra Healthcare REIT by 27.4% during the 2nd quarter. Franklin Resources Inc. now owns 503,499 shares of the real estate investment trust's stock worth $9,285,000 after purchasing an additional 108,268 shares during the period. Finally, Journey Strategic Wealth LLC grew its position in Sabra Healthcare REIT by 7.5% during the 2nd quarter. Journey Strategic Wealth LLC now owns 17,884 shares of the real estate investment trust's stock worth $330,000 after purchasing an additional 1,252 shares during the period. 99.40% of the stock is currently owned by institutional investors and hedge funds.
Sabra Healthcare REIT Trading Up 0.5%
Shares of Sabra Healthcare REIT stock opened at $19.69 on Tuesday. The firm has a 50-day simple moving average of $19.76 and a two-hundred day simple moving average of $19.06. The company has a market cap of $4.96 billion, a P/E ratio of 30.77, a price-to-earnings-growth ratio of 1.56 and a beta of 0.64. Sabra Healthcare REIT, Inc. has a fifty-two week low of $15.75 and a fifty-two week high of $21.07. The company has a debt-to-equity ratio of 0.90, a quick ratio of 4.29 and a current ratio of 4.29.
Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last posted its earnings results on Thursday, February 12th. The real estate investment trust reported $0.11 EPS for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Sabra Healthcare REIT had a net margin of 20.09% and a return on equity of 5.63%. The business had revenue of $201.35 million for the quarter, compared to analyst estimates of $201.97 million. During the same quarter last year, the business earned $0.36 earnings per share. Sabra Healthcare REIT's revenue was up 16.2% on a year-over-year basis. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. As a group, equities analysts predict that Sabra Healthcare REIT, Inc. will post 1.45 earnings per share for the current fiscal year.
Sabra Healthcare REIT Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Friday, February 13th were issued a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 6.1%. The ex-dividend date of this dividend was Friday, February 13th. Sabra Healthcare REIT's dividend payout ratio (DPR) is presently 187.50%.
Analysts Set New Price Targets
Several equities analysts have recently issued reports on the company. Jefferies Financial Group reissued a "buy" rating and issued a $22.00 price objective on shares of Sabra Healthcare REIT in a report on Monday, December 15th. Citigroup raised their target price on Sabra Healthcare REIT from $21.00 to $24.00 and gave the stock a "buy" rating in a report on Wednesday, February 18th. Citizens Jmp lifted their price target on Sabra Healthcare REIT from $22.00 to $23.00 and gave the company a "market outperform" rating in a research report on Wednesday, February 18th. Scotiabank boosted their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a "sector perform" rating in a report on Monday, March 2nd. Finally, Wall Street Zen lowered Sabra Healthcare REIT from a "hold" rating to a "sell" rating in a research report on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $21.90.
Get Our Latest Analysis on SBRA
Sabra Healthcare REIT Profile
(
Free Report)
Sabra Healthcare REIT, Inc NASDAQ: SBRA is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.
Serving a broad spectrum of care segments, Sabra's tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.
Featured Articles
Want to see what other hedge funds are holding SBRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sabra Healthcare REIT, Inc. (NASDAQ:SBRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sabra Healthcare REIT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sabra Healthcare REIT wasn't on the list.
While Sabra Healthcare REIT currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.